Sequencing cancer genomes to tailor treatments to individual patients Screening for hundreds of mutations in tumours is the most promising route to customised drug treatments for cancer.…
Forces driving the evolution of biologics into biosimilars and biobetters As demand for biologics increases, manufacturers are devising strategies to maximise their returns on investment and benefit patients.…
Criticism voiced over new rules for Cancer Drugs Fund Cancer charities and the pharmaceutical industry have expressed concerns over the way cancer medicines are appraised after a revised process for assessing drugs available through the Cancer Drugs Fund was published by NHS England.…
Eribulin improves survival in women with advanced breast cancer Eribulin improves overall survival in women with advanced breast cancer, with the greatest benefit seen in women with triple-negative disease, new research suggests.…
Public call for Roche to cut price of breast cancer drug An online petition calls on the drug company Roche to lower the price of its breast cancer drug Kadcyla to make it cheap enough to be made available on the NHS.…
‘Gene deserts’ are linked with breast cancer, research suggests Single-letter changes within long stretches of non-coding DNA affect how DNA loops together, physically interacting with target genes to influence their expression.…
Latest trials do not support link between bisphosphonate use and reduced breast cancer risk Randomised controlled trials fail to confirm association between osteoporosis treatments and decreased breast cancer risk in postmenopausal women.…
Use of newer oral contraceptives linked to higher breast cancer risk Oral contraceptive use is associated with a 50% increased risk of breast cancer compared with no use or former use.…
